Piper Sandler raised the firm’s price target on Labcorp (LH) to $280 from $260 and keeps a Neutral rating on the shares. The firm updated the company’s model post the earnings report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Positive Outlook for Labcorp Holdings: Buy Rating Affirmed Amid Solid Growth and Strategic Moves
- Labcorp price target raised to $267 from $253 at Baird
- Labcorp price target raised to $250 from $240 at Barclays
- Labcorp’s Resilience and Growth Potential: A Reliable Investment Choice Despite Revenue Miss
- Labcorp Holdings: Strong Q1 2025 Performance and Positive Outlook Justify Buy Rating